Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in <i>mdx</i> and <i>Cmah-/-mdx</i> mouse models of Duchenne muscular dystrophy - Fig 2

<p><b>A-D: P-PMO reduces fibrosis in early treated <i>Cmah-/-mdx</i> mice.</b> A) Treated and untreated <i>mdx</i> mice show a similar range of cardiac pathology but treated animals showed a distinct aspect of pathology- brown staining cells (yellow arrow) which are assumed to be cells rich in intrinsic pigment (such as melanin). H&E staining of heart demonstrating presence of fibrosis, necrotic fibres (green arrows) and (x10) Scale bar = 50 μm. B) Quantification of fibrosis on masson’s trichrome stained <i>Cmah-/-mdx</i> heart sections (*p<0.05, **p<0.01 different from <i>C57BL10</i>, ^P<0.05 different from <i>Cmah-/-mdx</i>, Unpaired Student’s t-tests) (n = 6-9/group) C) Masson’s trichrome stained sections of the most fibrotic animals in each group (Scale bar = 500 μm). D) P-PMO treatment does not significantly affect fibre size distribution (n = 6-9/group, 2-way ANOVA. Error bars represent SEM).